English version of this page

Inflammasjonsmarkører for hjertekar- og metabolske sykdommer

Vår forskning fokuserer på måling og bruk av betennelsesmarkører i ulike sykdomspopulasjoner preget av lav grad av systemisk inflammasjon.

Om gruppen

Våre fokusområder er kardiovaskulær sykdom og risiko, nevropsykiatriske lidelser, og metabolske endokrine sykdommer (hypofysesykdom).

Mange sykdomstilstander som er assosiert med lav grad av kronisk inflammasjon. Inflammasjonen kan føre til detekterbare endringer i inflammatoriske proteiner som kan måles i biologisk væske slik som serum og plasma, noe som gjør dem verdifulle biomarkører.

Måling av disse biomarkører kan derfor være nyttig for å oppdage sykdommer i tidlig fase og/eller tilby informasjon om mekanismer for sykdom. Disse kan også representere behandlingsmål eller være nyttig i vurderingen av behandlingstiltak og forutsi utfall.

Våre mål

  • Identifisere gode kardiovaskulære risikomarkører som tidlig kan identifisere pasienter med dårlig prognose eller fange opp subpopulasjoner som har spesielt god effekt av behandling.
  • Øke forståelsen for forskjellige fett-depoters og skjelettets bidrag til insulin resistens ved hypofyseforstyrrelser og etter svangerskap.

Gruppen tilhører Institutt for indremedisinsk forskning.

Prosjekter

  • Sirkulerende risikomarkører i forskjellige kardiovaskulære kohortstudier (PRAKSIS, CORONA, PLATO)
  • Sirkulerende risikomarkører ved KOLS
  • Wnt systemets betydning ved hjertesvikt og aterosklerose med fokus på løselige Wnt antagonister
  • Betydningen av inflammasjon ved insulin-resistens hos pasienter med hypofyseforstyrrelser (akromegali, Cushing syndrom)
  • EMT sin betydning for behandlingsrespons ved akromegali
  • Inflammasjon og psykiatri, samarbeid med TOP/Ullevål.
  • Inflammasjon ved CMV infeksjon etter nyre transplantasjon
  • Metabolsk og kardiovaskulær risiko etter normalt svangerskap (STORK)

Publikasjoner

  • Touw WA, Ueland T, Bollerslev J, Schousboe JT, Lim WH, Wong G, Thompson PL, Kiel DP, Prince RL, Rivadeneira F and Lewis JR. Association of Circulating Wnt Antagonists With Severe Abdominal Aortic Calcification in Elderly Women. Journal of the Endocrine Society. 2017;1:26-38.
  • Yardley M, Ueland T, Aukrust P, Michelsen A, Bjorkelund E, Gullestad L and Nytroen K. Immediate response in markers of inflammation and angiogenesis during exercise: a randomised cross-over study in heart transplant recipients. Open heart. 2017;4:e000635.
  • Farup PG, Ueland T, Rudi K, Lydersen S and Hestad K. Functional Bowel Disorders Are Associated with a Central Immune Activation. Gastroenterology research and practice. 2017;2017:1642912.
  • Sikkeland LIB, Borander AK, Voie OA, Aass HCD, Ovstebo R, Aukrust P, Longva K, Alexis NE, Kongerud J and Ueland T. Systemic and Airway Inflammation After Exposure to Fumes from Military Small Arms. American journal of respiratory and critical care medicine. 2017.
  • Lekva T, Michelsen AE, Aukrust P, Paasche Roland MC, Henriksen T, Bollerslev J and Ueland T. CXC chemokine ligand 16 is increased in gestational diabetes mellitus and preeclampsia and associated with lipoproteins in gestational diabetes mellitus at 5 years follow-up. Diabetes & vascular disease research. 2017;14:525-533.
  • Morch RH, Dieset I, Faerden A, Hope S, Aas M, Nerhus M, Gardsjord ES, Haram M, Falk RS, Joa I, Morken G, Agartz I, Aukrust P, Djurovic S, Melle I, Ueland T and Andreassen OA. Persistent increase in TNF and IL-1 markers in severe mental disorders suggests trait-related inflammation: a one year follow-up study. Acta psychiatrica Scandinavica. 2017;136:400-408.
  • Mayerhofer CCK, Ueland T, Broch K, Vincent RP, Cross GF, Dahl CP, Aukrust P, Gullestad L, Hov JR and Troseid M. Increased Secondary/Primary Bile Acid Ratio in Chronic Heart Failure. Journal of cardiac failure. 2017;23:666-671.
  • Aas M, Dieset I, Hope S, Hoseth E, Morch R, Reponen E, Steen NE, Laskemoen JF, Ueland T, Aukrust P, Agartz I, Andreassen OA and Melle I. Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses. Brain, behavior, and immunity. 2017;65:342-349.
  • Abraityte A, Lunde IG, Askevold ET, Michelsen AE, Christensen G, Aukrust P, Yndestad A, Fiane A, Andreassen A, Aakhus S, Dahl CP, Gullestad L, Broch K and Ueland T. Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated cardiomyopathy. Scientific reports. 2017;7:3490.
  • Ueland T, Laugsand LE, Vatten LJ, Janszky I, Platou C, Michelsen AE, Damas JK, Aukrust P and Asvold BO. Monocyte/macrophage and T cell activation markers are not independently associated with MI risk in healthy individuals - results from the HUNT Study. International journal of cardiology. 2017;243:502-504.
  • Auensen A, Hussain AI, Falk RS, Walle-Hansen MM, Bye J, Pettersen KI, Aukrust P, Ueland T and Gullestad LL. Associations of brain-natriuretic peptide, high-sensitive troponin T, and high-sensitive C-reactive protein with outcomes in severe aortic stenosis. PloS one. 2017;12:e0179304.
  • Norum HM, Broch K, Michelsen AE, Lunde IG, Lekva T, Abraityte A, Dahl CP, Fiane AE, Andreassen AK, Christensen G, Aakhus S, Aukrust P, Gullestad L and Ueland T. The Notch Ligands DLL1 and Periostin Are Associated with Symptom Severity and Diastolic Function in Dilated Cardiomyopathy. Journal of cardiovascular translational research. 2017;10:401-410.
  • Prebensen C, Troseid M, Ueland T, Dahm A, Sandset PM, Aaberge I, Waalen K, Dyrhol-Riise AM, Tasken K and Kvale D. Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. PloS one. 2017;12:e0176527.
  • Lekva T, Roland MCP, Michelsen AE, Friis CM, Aukrust P, Bollerslev J, Henriksen T and Ueland T. Large Reduction in Adiponectin During Pregnancy Is Associated With Large-for-Gestational-Age Newborns. The Journal of clinical endocrinology and metabolism. 2017;102:2552-2559.
  • Holte E, Kleveland O, Ueland T, Kunszt G, Bratlie M, Broch K, Michelsen AE, Bendz B, Amundsen BH, Aakhus S, Damas JK, Gullestad L, Aukrust P and Wiseth R. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction. Heart (British Cardiac Society). 2017;103:1521-1527.
  • Ueland T, Laugsand LE, Vatten LJ, Janszky I, Platou C, Michelsen AE, Damas JK, Aukrust P and Asvold BO. Extracellular matrix markers and risk of myocardial infarction: The HUNT Study in Norway. European journal of preventive cardiology. 2017;24:1161-1167.
  • Nymo SH, Aukrust P, Kjekshus J, McMurray JJ, Cleland JG, Wikstrand J, Muntendam P, Wienhues-Thelen U, Latini R, Askevold ET, Gravning J, Dahl CP, Broch K, Yndestad A, Gullestad L and Ueland T. Limited Added Value of Circulating Inflammatory Biomarkers in Chronic Heart Failure. JACC Heart failure. 2017;5:256-264.
  • Abraityte A, Vinge LE, Askevold ET, Lekva T, Michelsen AE, Ranheim T, Alfsnes K, Fiane A, Aakhus S, Lunde IG, Dahl CP, Aukrust P, Christensen G, Gullestad L, Yndestad A and Ueland T. Wnt5a is elevated in heart failure and affects cardiac fibroblast function. Journal of molecular medicine (Berlin, Germany). 2017;95:767-777.
  • Shetelig C, Limalanathan S, Eritsland J, Hoffmann P, Seljeflot I, Gran JM, Aukrust P, Ueland T and Andersen GO. Osteoprotegerin levels in ST-elevation myocardial infarction: Temporal profile and association with myocardial injury and left ventricular function. PloS one. 2017;12:e0173034.
  • Shahini N, Michelsen AE, Nilsson PH, Ekholt K, Gullestad L, Broch K, Dahl CP, Aukrust P, Ueland T, Mollnes TE, Yndestad A and Louwe MC. The alternative complement pathway is dysregulated in patients with chronic heart failure. Scientific reports. 2017;7:42532.
  • Vesterhus M, Holm A, Hov JR, Nygard S, Schrumpf E, Melum E, Thorbjornsen LW, Paulsen V, Lundin K, Dale I, Gilja OH, Zweers S, Vatn M, Schaap FG, Jansen PLM, Ueland T, Rosjo H, Moum B, Ponsioen CY, Boberg KM, Farkkila M, Karlsen TH and Lund-Johansen F. Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. Journal of hepatology. 2017;66:1214-1222.
  • Lekva T, Michelsen AE, Aukrust P, Henriksen T, Bollerslev J and Ueland T. Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus. Cardiovascular diabetology. 2017;16:5.
  • Broch K, Leren IS, Saberniak J, Ueland T, Edvardsen T, Gullestad L and Haugaa KH. Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2017;22:367-371.
  • Hoseth EZ, Ueland T, Dieset I, Birnbaum R, Shin JH, Kleinman JE, Hyde TM, Morch RH, Hope S, Lekva T, Abraityte AJ, Michelsen AE, Melle I, Westlye LT, Ueland T, Djurovic S, Aukrust P, Weinberger DR and Andreassen OA. A Study of TNF Pathway Activation in Schizophrenia and Bipolar Disorder in Plasma and Brain Tissue. Schizophrenia bulletin. 2017;43:881-890.
  • Kiani AN, Aukrust P, Ueland T, Hollan I, Barr E, Magder LS and Petri M. Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus. Lupus. 2017;26:865-870.
  • Eide IA, Asberg A, Svensson M, Ueland T, Mollnes TE, Hartmann A, Bjerve KS, Michelsen A, Aukrust P, Christensen JH, Schmidt EB and Jenssen T. Plasma Levels of Marine n-3 Fatty Acids Are Inversely Correlated With Proinflammatory Markers sTNFR1 and IL-6 in Renal Transplant Recipients. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2017;27:161-168.
  • Arain F, Gullestad L, Nymo S, Kjekshus J, Cleland JG, Michelsen A, McMurray JJ, Wikstrand J, Aukrust P and Ueland T. Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2017;22:261-267.
Publisert 12. mai 2014 10:18 - Sist endret 14. aug. 2018 09:31

Kontakt

Gruppeleder